Key result
CYP2C19 resistant alleles in ~28% of patients are linked to variable platelet inhibition by clopidogrel.
Why the study?
The study was conducted to determine the distribution of genetic polymorphisms in CYP2C19 in Iraqi patients and their role in inter-individual variability of clopidogrel efficacy.
Does CYP2C19 polymorphism affect platelet aggregation inhibition by clopidogrel in Iraqi patients at high risk of cardiovascular diseases?
Population
100 patients under high risk of cardiovascular diseases starting clopidogrel prophylactic therapy
Comparison
CYP2C19 genetic polymorphisms
Design
Prospective controlled study
Follow-up
One-month post-therapy
Authors
Loading...
May support CYP2C19 testing in high-risk Iraqi patients; leaves open whether genotype-guided therapy improves outcomes.
Cohort (n=100)
Does CYP2C19 polymorphism affect platelet aggregation inhibition by clopidogrel in Iraqi patients at high risk of cardiovascular diseases?
In an Iraqi cohort, 28% of patients possessed clopidogrel-resistant CYP2C19 alleles (*2 and *3), highlighting the potential utility of genetic testing and VASP index monitoring to optimize antiplatelet therapy.
Aga et al. (2020) conducted a cohort in High risk of cardiovascular diseases (n=100). CYP2C19 genetic polymorphisms (CYP2C19*2 and CYP2C19*3 alleles) vs. CYP2C19*1 allele was evaluated on Vasodilator-stimulated phosphoprotein (VASP) index. CYP2C19*2 and CYP2C19*3 resistant alleles were present in 28% of patients, contributing to inter-individual variability in platelet inhibition by clopidogrel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: